You are here: Industry Insights > Pancreatic cancer

News List

RenovoRx Announces Orphan Drug Designation Granted for Treating Bile Duct Cancer americanpharmaceuticalreview
June 15, 2020
RenovoRx announced the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for treating bile duct cancer, also known as cholangiocarcinoma, with intra-arterial gemcitabine.
Lynparza Recommended for Approval in EU by CHMP for BRCA-Mutated Metastatic Pancreatic Cancer americanpharmaceuticalreview
June 10, 2020
AstraZeneca and Merck announced Lynparza (olaparib) has been recommended for marketing authorization in the European Union (EU) for the 1st-line maintenance treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.
CSIR’s anti-cancer drug IIIM-290 goes into clinical trial expresspharma
June 09, 2020
The clinical trial aims to assess safety, tolerability and exposure of the compound in humans along with the early efficacy indicators in pancreatic cancer patients.
Lynparza backed by CHMP for BRCA-mutated pancreatic cancer pharmatimes
June 02, 2020
AstraZeneca and MSD's Lynparza (olaparib) has been recommended for marketing authorisation in the EU for the first-line maintenance treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.
CytRx Begins Aldoxorubicin Phase 2 Study americanpharmaceuticalreview
May 27, 2020
CytRx highlighted that ImmunityBio and NantKwest announced the initiation of a Phase 2 randomized, two-cohort, open-label study for first and second-line treatment of locally advanced or metastatic pancreatic cancer (QUILT-88).
75 percent of nanopharmaceuticals are being developed for oncology europeanpharmaceuticalreview
April 09, 2020
A report states that three quarters of the roughly 230 nanopharmaceuticals in clinical development are for use as targeted cancer therapeutics.
Lynparza Granted Orphan Drug Designation in Japan for Pancreatic Cancer americanpharmaceuticalreview
March 23, 2020
AstraZeneca announced Lynparza (olaparib) has been granted orphan drug designation (ODD) in Japan for the maintenance treatment of germline BRCA-mutated (gBRCAm) curatively unresectable pancreatic cancer.
Opdivo, cabiralizumab combo falls short in pancreatic cancer pharmatimes
March 10, 2020
Bristol-Myers Squibb has revealed that its Phase II trial testing the combination of cabiralizumab with Opdivo (nivolumab) with and without chemotherapy in patients with advanced pancreatic cancer has fallen short of success.
BioLineRx Receives Orphan Drug Designation for Motixafortide for Pancreatic Cancer in Europe americanpharmaceuticalreview
January 19, 2020
BioLineRx announced the European Commission (EC) has granted Orphan Drug Designation to its lead oncology candidate, Motixafortide (BL-8040), for the treatment of pancreatic cancer, based on a positive opinion from the Committee for ...
4D Announce New Study of MRx0518 in Pancreatic Cancer americanpharmaceuticalreview
January 07, 2020
4D pharma announced the opening of a clinical study to evaluate the safety and preliminary clinical efficacy of MRx0518 in combination with preoperative radiotherapy in 15 patients with resectable pancreatic cancer.

Previous page 1 2 3 4 5 6 Next page